References
1. Kornbluth A, Sachar DB; Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2004;99:1371-1385.
2. Hanauer SB, Sandborn W; Practice Parameters Committee of the American College of Gastroenterology. Management of Crohn"s disease in adults. Am J Gastroenterol. 2001;96:635-643.
3. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology. 2004;126:1504-1517.
4. Ekbom A. The epidemiology of IBD: a lot of data but little knowledge. How shall we proceed? Inflamm Bowel Dis. 2004;10 [Suppl 1]:S32-S34.
5. Heresbach D, Alexandre JL, Bretagne JF, et al. Crohn"s disease in the over-60 age group: a population based study. Eur J Gastroenterol Hepatol . 2004;16:657-664.
6. Basu D, Lopez I, Kulkarni A, Sellin JH. Impact of race and ethnicity on inflammatory bowel disease. Am J Gastroenterol. 2005;100:2254-2261.
7. Calkins BM. A meta-analysis of the role of smoking in inflammatory bowel disease. Dig Dis Sci. 1989;34:1841-1854.
8. Gibson PR, Shepherd SJ. Personal view: food for thought--western lifestyle and susceptibility to Crohn"s disease. The FODMAP hypothesis. Aliment Pharmacol Ther. 2005;21:1399-1409.
9. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology. 1998;115:182-205.
10. Hanauer SB, Sandborn W. Management of Crohn"s disease in adults. Am J Gastroenterol.2001;96:635-643.
11. Summers RW, Switz DM, Sessions JT Jr, et al. National Cooperative Crohn"s Disease Study: results of drug treatment. Gastroenterology. 1979;77:847-869.
12. Landi B, Anh TN, Cortot A, et al. Endoscopic monitoring of Crohn"s disease treatment: a prospective, randomized clinical trial. The Groupe d"Etudes Therapeutiques des Affections Inflammatoires Digestives. Gastroenterology . 1992;102:1647-1653.
13. Steinhart AH, Ewe K, Griffiths AM, et al. Corticosteroids for maintenance of remission in Crohn"s disease. Cochrane Database Syst Rev. 2003:CD000301.
14. Bernstein CN, Leslie WD, Leboff MS. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology. 2003;124:795-841.
15. Otley A, Steinhart AH. Budesonide for induction of remission in Crohn"s disease. Cochrane Database Syst Rev. 2005 Oct 19:CD000296.
16. Chopra A, Pardi DS, Loftus EV Jr, et al. Budesonide in the treatment of inflammatory bowel disease: the first year of experience in clinical practice. Inflamm Bowel Dis. 2006;12:29-32.
17. Akobeng AK, Gardener E. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn"s Disease. Cochrane Database Syst Rev. 2005:CD003715.
18. Singleton JW, Hanauer SB, Gitnick GL, et al. Mesalamine capsules for the treatment of active Crohn"s disease: results of a 16-week trial. Pentasa Crohn"s Disease Study Group. Gastroenterology. 1993;104:1293-1301.
19. Messori A, Brignola C, Trallori G, et al. Effectiveness of 5-aminosalicylic acid for maintaining remission in patients with Crohn"s disease: a meta-analysis. Am J Gastroenterol. 1994;89(5):692-698.
20. Steinhart AH, Hemphill D, Greenberg GR. Sulfasalazine and mesalazine for the maintenance therapy of Crohn"s disease: a meta-analysis. Am J Gastroenterol. 1994;89:2116-2124.
21. Kamm MA. Review article: chronic active disease and maintaining remission in Crohn"s disease. Aliment Pharmacol Ther. 2004;20 [Suppl 4]:102-105.
22. Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn"s disease. A meta-analysis. Ann Intern Med . 1995;123:132142.
23. Pearson DC, May GR, Fick G, Sutherland LR. Azathioprine for maintaining remission of Crohn"s disease. Cochrane Database Syst Rev. 2000:CD000067.
24. Aberra FN, Lichtenstein GR. Review article: monitoring of immunomodulators in inflammatory bowel disease. Aliment Pharmacol Ther. 2005;21:307-319.
25. Siegel CA, Sands BE. Review article: practical management of inflammatory bowel disease patients taking immunomodulators. Aliment Pharmacol Ther. 2005;22:1-16.
26. Sun JH, Das KM. Low-dose oral methotrexate for maintaining Crohn"s disease remission: where we stand. J Clin Gastroenterol. 2005;39:751-756.
27. Vandeputte L, D"Haens G, Baert F, et al. Methotrexate in refractory Crohn"s disease. Inflamm Bowel Dis. 1999;5:11-15.
28. Brynskov J, Freund L, Rasmussen SN, et al. A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn"s disease. N Engl J Med. 1989;321:845-850.
29. Brynskov J, Freund L, Norby Rasmussen S, et al. Final report on a placebo-controlled, double-blind, randomized, multicentre trial of cyclosporin treatment in active chronic Crohn"s disease. Scand J Gastroenterol . 1991;26:689-695.
30. Loftus CG, Egan LJ, Sandborn WJ. Cyclosporine, tacrolimus, and mycophenolate mofetil in the treatment of inflammatory bowel disease. Gastroenterol Clin North Am. 2004;33:141-169.
31. Wild GE. The role of antibiotics in the management of Crohn"s disease. Inflamm Bowel Dis. 2004;10:321-323.
32. Sutherland L, Singleton J, Sessions J, et al. Double blind, placebo controlled trial of metronidazole in Crohn"s disease. Gut. 1991;32:1071-1075.
33. Prantera C, Berto E, Scribano ML, Falasco G. Use of antibiotics in the treatment of active Crohn"s disease: experience with metronidazole and ciprofloxacin. Ital J Gastroenterol Hepatol. 1998;30:602-606.
34. Gionchetti P, Rizzello F, Morselli C, et al. Management of inflammatory bowel disease: does rifaximin offer any promise? Chemotherapy. 2005;51[Suppl]1:96-102.
35. Shafran I, Johnson LK. An open-label evaluation of rifaximin in the treatment of active Crohn"s disease. Curr Med Res Opin. 2005;21:1165-1169.
36. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn"s disease. Crohn"s Disease cA2 Study Group. N Engl J Med. 1997;337:1029-1035.
37. Nikolaus S, Raedler A, Kuhbacker T, et al. Mechanisms in failure of infliximab for Crohn"s disease. Lancet. 2000;356:1475-1479.
38. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn"s disease: the ACCENT I randomised trial. Lancet. 2002;359:1541-1549.
39. Colombel JF, Loftus EV Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn"s disease: the Mayo clinic experience in 500 patients. Gastroenterology. 2004;126:19-31.
40. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med . 2001;345:1098-1104.
41. Sandborn WJ, Hanauer S, Loftus EV Jr, et al. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn"s disease. Am J Gastroenterol. 2004;99:1984-1989.
42. Papadakis KA, Shaye OA, Vasiliauskas EA, et al. Safety and efficacy of adalimumab (D2E7) in Crohn"s disease patients with an attenuated response to infliximab. Am J Gastroenterol. 2005;100:75-79.
43. Meier R, Steuerwald M. Place of probiotics. Curr Opin Crit Care. 2005;11:318-325.
44. Yamamoto, T. Factors affecting recurrence after surgery for Crohn"s disease. World J Gastroenterol. 2005;11:3971-3979.
http://www.uspharmacist.com/index.asp?show=article&page=8_1941.htm
http://www.mahyanews.com/images/stories/chart%202.bmpآدرس شکل 1